<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152694</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00077498</org_study_id>
    <nct_id>NCT04152694</nct_id>
  </id_info>
  <brief_title>Ceftaroline Pharmacokinetics in Continuous Renal Replacement Therapy</brief_title>
  <official_title>Ceftaroline Pharmacokinetics in Critically Ill Patients Receiving Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dosing of ceftaroline in patients with chronic kidney disease is defined, but there is no
      data on pharmacokinetics and pharmacodynamics of the drug in patients receiving continuous
      renal replacement therapy (CRRT). The purpose of this study is to determine pharmacokinetics
      and pharmacodynamics of ceftaroline in a critically ill patient population receiving CRRT, in
      order to define a dosing recommendation in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ceftaroline fosamil is a time-dependent, hydrophilic, bactericidal fifth generation
      cephalosporin that was FDA approved in 2010 for community acquired pneumonia and skin and
      skin structure infections. Ceftaroline is FDA approved for both Gram-positive and
      Gram-negative organisms. Gram-positive organisms covered are Staphylococcus aureus
      (methicillin resistant and methicillin sensitive strains), Streptococcus agalactiae,
      Streptococcus pneumonia, and Streptococcus pyogenes. Gram-negative coverage includes
      Escherichia coli, Haemophilus influenza, Klebsiella pneumonia, and Klebsiella oxytoca. In
      order for ceftaroline to exhibit effective bacterial killing, it requires that a certain
      percentage of the dosing interval is spent above the MIC.

      Dosing of ceftaroline in patients with chronic kidney disease is defined, but there is no
      data on pharmacokinetics and pharmacodynamics of the drug in patients receiving continuous
      renal replacement therapy (CRRT). The purpose of this study is to determine pharmacokinetics
      and pharmacodynamics of ceftaroline in a critically ill patient population receiving CRRT, in
      order to define a dosing recommendation in this population. CRRT modes that patients may be
      receiving in this trial include: continuous veno-venous hemofiltration (CVVH), continuous
      veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Anticipated">November 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Half-life</measure>
    <time_frame>1 year</time_frame>
    <description>Ceftaroline elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Clearance</measure>
    <time_frame>1 year</time_frame>
    <description>Ceftaroline clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Volume of distribution</measure>
    <time_frame>1 year</time_frame>
    <description>Ceftaroline volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Sieving coefficient</measure>
    <time_frame>1 year</time_frame>
    <description>Continuous renal replacement therapy modality sieving coefficient for ceftaroline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ceftaroline pharmacodynamics in patients receiving continuous renal replacement therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of time ceftaroline levels are above the minimum inhibitory concentration for the most likely pathogen(s)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Infection During Renal Replacement Therapy</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Ceftaroline in CRRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ceftaroline levels measured in patients receiving continuous renal replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ceftaroline levels in CRRT</intervention_name>
    <description>Levels of ceftaroline measured in patients receiving CRRT</description>
    <arm_group_label>Ceftaroline in CRRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to an intensive care unit

          -  Receiving CRRT (CVVH, CVVHDF, CVVHD)

          -  Receiving ceftaroline

        Exclusion Criteria:

          -  Pregnant patients

          -  Burn patients

          -  Patients with toxic epidermal necrolysis or Stevens-Johnson syndrome

          -  Patients prescribed extended infusion ceftaroline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mojdeh Heavner</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mojdeh S Heavner, PharmD</last_name>
    <phone>410-706-3498</phone>
    <email>mheavner@rx.umaryland.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojdeh Heavner</last_name>
      <email>mheavner@rx.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Mojdeh Heavner</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftaroline fosamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

